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Coding Variants at Hexa-allelic Amino Acid 13
of HLA-DRB1 Explain Independent SNP
Associations with Follicular Lymphoma Risk
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Hans-Olov Adami,8,11 Bengt Glimelius,4 Chiea Chuen Khor,1,12,13,14 Henrik Hjalgrim,10
Leonid Padyukov,15 Keith Humphreys,8 Gunilla Enblad,4 Christine F. Skibola,7,18
Paul I.W. de Bakker,5,6,16,18 and Jianjun Liu1,14,18,*
Non-Hodgkin lymphoma represents a diverse group of blood malignancies, of which follicular lymphoma (FL) is a common subtype.
Previous genome-wide association studies (GWASs) have identified in the human leukocyte antigen (HLA) class II region multiple inde-
pendent SNPs that are significantly associated with FL risk. To dissect these signals and determine whether coding variants in HLA genes
are responsible for the associations, we conducted imputation, HLA typing, and sequencing in three independent populations for a total
of 689 cases and 2,446 controls. We identified a hexa-allelic amino acid polymorphism at position 13 of the HLA-DR beta chain that
showed the strongest association with FL within the major histocompatibility complex (MHC) region (multiallelic p ¼ 2.3 3 1015).
Out of six possible amino acids that occurred at that position within the population, we classified two as high risk (Tyr and Phe),
two as low risk (Ser and Arg), and two as moderate risk (His and Gly). There was a 4.2-fold difference in risk (95% confidence
interval ¼ 2.9–6.1) between subjects carrying two alleles encoding high-risk amino acids and those carrying two alleles encoding
low-risk amino acids (p ¼ 1.01 3 1014). This coding variant might explain the complex SNP associations identified by GWASs and
suggests a common HLA-DR antigen-driven mechanism for the pathogenesis of FL and rheumatoid arthritis.Four genome-wide association studies (GWASs) have
recently revealed complex associations between genetic
variants in the human leukocyte antigen (HLA) region
and follicular lymphoma (FL [MIM 613024]) risk,1–4
particularly two independent associations tagged by
rs104845611 and rs26470122 within the HLA class II re-
gion. Further imputation with tag SNPs1,5 and HLA
typing6 revealed that coding-sequence variation in the
molecules encoded by the extended HLA-DRB1*0101-
HLA-DQA1*0101-HLA-DQB1*0501 haplotype might be
responsible for the association at rs10484561 and that
the DRB1*15-DQA1*01-DQB1*06 haplotype might partly
explain the association at rs2647012.6 A recent analysis
also observed the association between gene-expression
changes and rs2647012, but not rs10484561.7 These previ-
ous findings indicate an important role of genetic variation
in the HLA class II region in FL pathogenesis, but the un-
derlying causal variants that drive the association are still
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The Amallele is defined by a precise combination of coding differ-
ences at various amino acid (AA) positions in the encoded
HLA molecules, and it is possible that changes at the AA
level might impact antigen binding and therefore influ-
ence disease pathogenesis through altered immune
response.
To determine whether specific coding variants within
HLA genes contribute to the diverse association signals,
we imputed dense SNPs (by using 1000 Genomes Project
data8) and classical HLA alleles and coding variants across
the HLA region (b36, chr6: 20–40Mb) in our GWAS discov-
ery sample of 379 cases and 791 controls2 from Sweden
and Denmark (the Scandinavian Lymphoma Etiology
[SCALE] study). Imputation of classical HLA alleles and
their constituent single-nucleotide variants and corre-
sponding AAs was performed with BEAGLE as previously
described.9,10 The reference panel was constructed with
the use of genotype data from the Major Histocompatibil-
ity Complex (MHC)Working Group of the Type 1 Diabetesology, and Research, Singapore 138672, Singapore; 2Clinical Epidemiology
eden; 3Division of Environmental Health Sciences, School of Public Health,
adiology, Oncology, and Radiation Science, Uppsala University, Uppsala SE-
rd Medical School, Boston, MA 02115, USA; 6Broad Institute of Harvard and
blic Health, University of Alabama at Birmingham, Birmingham, AL 35294,
titutet, Stockholm SE-171 77, Sweden; 9Department of Epidemiology and
USA; 10Department of Epidemiology Research, Statens Serum Institut, Co-
sity, Boston, MA 02115, USA; 12Singapore Eye Research Institute, Singapore
Medicine, National University of Singapore, Singapore 119074, Singapore;
National University of Singapore, Singapore 117597, Singapore; 15Rheuma-
versity Hospital Solna, Stockholm SE-171 76, Sweden; 16Department of Med-
t 3584 CX, the Netherlands
y of Human Genetics. All rights reserved.
erican Journal of Human Genetics 93, 167–172, July 11, 2013 167
Table 1. Association Statistics from Testing Protective Alleles versus All Others and Risk Alleles versus All Others at AA 13 of HLA-DRB1
No. of Cases (Frequency) No. of Controls (Frequency) OR (95% CI) Trend Test p Value
Ser þ Arg at AA 13
Discovery 379 (0.379) 791 (0.509) 0.591 (0.495–0.707) 7.83 3 109
dosage: 8.26 3 109
Replication 1 222 (0.439) 220 (0.573) 0.584 (0.446–0.766) 1.01 3 104
Replication 2 88 (0.403) 1,435 (0.515) 0.640 (0.469–0.872) 4.69 3 103
Meta-analysis p OR Phet I
2
6.51 3 1014 0.598 0.893 0
Tyr þ Phe at AA 13
Discovery 379 (0.326) 791 (0.228) 1.660 (1.363–2.020) 4.87 3 107
dosage: 4.69 3 107
Replication 1 222 (0.365) 220 (0.239) 1.822 (1.355–2.450) 7.15 3 105
Replication 2 88 (0.375) 1,435 (0.226) 1.954 (1.437–2.660) 1.90 3 105
Meta-analysis p OR Phet I
2
2.00 3 1014 1.760 0.659 0
Abbreviations are as follows: OR, odds ratio; CI, confidence interval; AA, amino acid; Phet, Cochran’s Q test p value; and I
2, inconsistency measure.Genetics Consortium; these data consist of 2,537 SNPs
genotyped in the MHC region and classical types at 4-digit
resolution from 11,173 individuals. On the basis of the
EMBL-EBI Immunogenetics HLA Database, AA variants
(based on codons) were coded as binary markers (present
or absent) in the reference panel. The final reference panel
for imputation contained 2,767 unrelated founder individ-
uals of European descent from collections across Europe,
the United Kingdom, and North America9,10 and data for
263 classical HLA alleles and 372 AA positions. We used
default parameters for BEAGLE (ten iterations of phasing
and imputation and testing four pairs of haplotype pairs
for each individual at each iteration)9,10 (average BEAGLE
r2 ¼ 0.96). SNPs were imputed with IMPUTE2 (v.2.2.2)11
on the basis of phased genotype data from the 1000 Ge-
nomes Project Phase I integrated variant set v.38 (average
info score for SNPs with MAF > 0.01 ¼ 0.90). We set all
SNP genotypes imputed with genotype probability lower
than 0.9 to missing and analyzed all imputed HLA geno-
types. SNPs imputed with an info score < 0.8 in IMPUTE2,
>10% missing data, or MAF < 0.01 were excluded from
further analyses. A total of 71,954 SNPs (average info
score ¼ 0.97), 263 classical HLA alleles (two- and four-digit
resolution), and 372 AA positions were imputed. Of these,
86 AA positions were ‘‘multiallelic,’’ i.e., had three to six
different residues encoded at each position across all our
samples.
We conducted trend tests on all the imputed biallelic
variants while adjusting for PC1-3 as covariates2 (genomic
inflation in the GWAS ¼ 1.028). For multiallelic AA sites
(triallelic, quadrallelic, penta-allelic, or hexa-allelic), we
performed the global multiallelic test at each site and
further tested every possible combination of one, two, or168 The American Journal of Human Genetics 93, 167–172, July 11, 2three encoded AAs against the rest. Association tests were
performed on both the best-guess genotypes and the allelic
dosages as determined from the imputed genotype proba-
bilities, which accounted for any uncertainties in the
imputed genotypes. The results were checked for consis-
tency between the two methods, and the results from
best-guess genotypes were presented. We also performed
global multiallelic (genotypic) tests while taking into ac-
count all alleles at each multiallelic position. The multial-
lelic test was performed as follows: convert k-alleles to
k-1 bialleles, invoke the glm function in R to estimate
the multivariate model, and use the likelihood ratio test
to compute the global multiallelic test p values. We per-
formed all conditional logistic regression analyses with
PLINK12 by entering any five out of six alleles encoding
AA 13 as covariates. Pairwise linkage disequilibrium (LD;
r2) between SNPs and alleles were measured in PLINK.
Among all the variants tested, the top signal of associa-
tion came from a combination of two possible genotypes,
coding for either Ser or Arg at the hexa-allelic AA 13
encoded by exon 2 of HLA-DRB1 (MIM 142857). This
variant showed stronger association (Table 1; pSerþArg13 ¼
7.8 3 109, odds ratio [OR] ¼ 0.59; 95% confidence inter-
val [CI] ¼ 0.50–0.70) than any other HLA variant or SNP
(genotyped or imputed) tested in our study and the
strongest association in global multiallelic tests across all
AA positions (multiallelic p ¼ 7.4 3 108). AA 13 geno-
types accounted for slightly more variance in FL risk
(3.1%) than both rs2647012 and rs10484561 combined
(3.0%). The strongest-associated imputed classical HLA
allele across all two- and four-digit alleles was HLA-
DQB1*06 (OR ¼ 0.63; 95% CI ¼ 0.51–0.78; p ¼ 2.05 3
105), which could be accounted for by rs2647012 alone013
Figure 1. Allele Frequencies at Hexa-Allelic AA 13
Allele frequencies of each AA at position 13 in (A) the SCALE
GWAS discovery data set (379 cases and 791 controls), (B) the
San Francisco data set (222 cases and 220 controls), and (C) the
Swedish validation data set (88 cases and 1,435 controls) and asso-
ciation p values from the global multiallelic test.(ORadj rs2647012 ¼ 0.86; 95% CI ¼ 0.65–1.15; padj rs2647012 ¼
0.32). The top imputed SNP was rs9268839, in complete
LD (r2 ¼ 1; crude OR ¼ 1.64; 95% CI ¼ 1.37–1.95; p ¼
4.57 3 108) with rs9378212 (which we previously
reported and validated technically by Taqman genotyp-
ing2) and partially correlated with rs2647012 (r2 ¼ 0.56)
and rs10484561 (r2 ¼ 0.15) (ORadj 2snps ¼ 1.25; 95% CI ¼
0.94–1.64; padj 2snps ¼ 0.12). The FL-associated HLA SNPs
reported in a recent GWAS4 were also not independent of
these previously reported SNPs in our data set (Table S1,
available online).The AmSix alleles were present at AA position 13 within our
samples and in the reference panel;9,10 those encoding
Ser and Arg showed low risk of FL, those encoding Tyr
and Phe showed high risk, and those encoding His and
Gly showed moderate risk (Figure 1, Table S2, and
Figure S2). Conditioning upon the alleles at position 13
was sufficient to eliminate all the association signals
within the vicinity in our study (chr6: 32–33 Mb; Table
S3 and Figure S1). Dosage analyses (Table 1), HLA
typing,10 and sequencing analyses13,14 confirmed high
accuracy of the imputation (BEAGLE r2 ¼ 0.99) at this po-
sition and high genotype concordance across these plat-
forms (~98%; see below).
To validate the associations, we evaluated genotypes at
AA 13 in two independent data sets of 222 FL cases and
220 controls from San Francisco6 (replication 1) and 88
FL cases and 1,435 controls from Sweden (replication 2)
by using a combination of Sanger sequencing (replication
2 cases),13,14 canonical HLA typing (replication 2 con-
trols),10 and GS-FLX sequencing (replication 1).6 Replica-
tion 1 included non-Hispanic white FL cases and controls
who were part of a population-based case-control non-
Hodgkin lymphoma (NHL) study conducted in the San
Francisco Bay Area from 2001 to 2006.6 Controls were
matched according to the number or frequency of cases
in 5-year age groups, sex, and county of residence. We
carried out HLA typing in these samples by using the
Roche high-resolution HLA primer set and subsequently
performed GS-FLX sequencing as previously described.6
Replication 2 included 19- to 83-year old (median age ¼
58 years) FL cases of Swedish descent and with available
fresh frozen tumor material assembled in the Uppsala-
O¨rebro region from 1970 to 2006;15 these cases were typed
by PCR amplification and Sanger sequencing (replication
2). Primer sequences for the amplification of HLA-DRB1
exon 2 were obtained from previously published
work.13,14 PCR products were purified with the use of
AMPure XP (Agencourt) solid-phase-reversible-immobili-
zation beads and run on a Bioanalyzer (Agilent) or 15%
polyacrylamide gel for ensuring that excess primers were
removed prior to sequencing. Sequence reads were visually
inspected at the codon position encoding AAs 11 and 13,
and genotypes were manually called (Figure S3) on the
basis of expected codons at both positions and flanking
ones according to sequences from the EMBL-EBI Immuno-
genetics HLA Database. For controls in replication 2, we
used a second independent set of 1,435 Swedish control
subject samples collected within the Epidemiological
Investigation of Rheumatoid Arthritis (EIRA) study from
1995 to 2006. HLA typing was carried out in the control
samples from the EIRA study with the use of sequence-
specific primer PCR (DR low-resolution kit; Olerup SSP)
as previously described.16 All discovery and replication
studies were conducted in accordance with the ethical
standards of the respective institutional review board of
each institution, and informed consent was obtained
from study participants.erican Journal of Human Genetics 93, 167–172, July 11, 2013 169
We first tested the accuracy of the imputed genotypes by
amplification and Sanger sequencing13,14 of DRB1 exon 2
in a subset of our discovery samples. We observed high
concordance between imputed genotypes and those in-
ferred from the sequence chromatograms (Figure S3)
(n ¼ 92, 98.4% allelic, 97% genotypic concordance) and
those inferred from HLA types8 (Table S6; n ¼ 596,
98.6% allelic, 97.3% genotypic concordance), confirming
the high accuracy of the imputed genotypes and the reli-
ability of the association results in our samples. To assess
the accuracy of the AA genotypes inferred from canonical
HLA typing data, we also Sanger sequenced a subset of 189
EIRA controls and found the alleles to be 97.6% concor-
dant; hence, there are not likely to be any major biases
because of the use of different genotyping platforms in
replication 2.
We observed consistent direction of associations at all of
the high- and low-risk residues at AA 13 across the three
study populations (Figure 1, Table S2). Although the asso-
ciation did not reach statistical significance for some of
the individual alleles (Table S2), it remained significant
for the combined protective (encoding Ser or Arg) and
risk (encoding Tyr or Phe) alleles in all the studies (Table
1). In the meta-analysis of all three populations, there
was strong evidence of association between the AA 13
polymorphism and FL risk and no evidence of heterogene-
ity (multiallelic p ¼ 2.3 3 1015; pSerþArg13 ¼ 6.5 3 1014;
ORSerþArg13 ¼ 0.60; heterogeneity I2 ¼ 0) (Table 1). Across
the three data sets, there was a 4.2-fold difference in risk
(95% CI ¼ 2.9–6.1) between subjects carrying two high-
risk alleles and those carrying two low-risk alleles (Co-
chran-Mantel-Haenszel p ¼ 1.01 3 1014).
Conditional analyses followed by meta-analyses across
all three data sets suggested that the AA 13 polymorphism
might fully explain associations observed at SNPs
rs2647012 (p ¼ 4.72 3 1011 before adjustment; p ¼
0.804 after adjustment) and rs10484561 (p ¼ 2.61 3
1011 before adjustment; p ¼ 0.356 after adjustment) (Ta-
ble S3). However, there was evidence of heterogeneity in
the results of the conditional analysis across the three
data sets (Q < 0.05; I2 > 70%). In particular, there was
residual association at rs10484561 and rs2647012 after
adjustment for the genetic effects at AA 13 in the replica-
tion 1 data set (Table S3). Conversely, conditioning on ge-
notypes at rs2647012 (multiallelic p ¼ 1.68 3 107),
rs10484561 (multiallelic p ¼ 7.58 3 107), or both SNPs
(multiallelic p ¼ 0.005) did not fully eliminate the associa-
tion observed at AA 13, suggesting that the genotypes at
AA 13 are well tagged, but not fully tagged, by these two
SNPs.
Further haplotype analysis indicated that the minor C
allele at rs10484561 partially tags the haplotypes carrying
the high-risk allele encoding Phe (OR ¼ 1.81; 95% CI ¼
1.51–2.18), whereas the minor T allele at rs2647012
partially tags the haplotypes carrying the low-risk alleles
encoding Ser (OR ¼ 0.69; 95% CI ¼ 0.59–0.81) and Arg
(OR ¼ 0.67; 95% CI ¼ 0.55–0.82) (Table S4). For this anal-170 The American Journal of Human Genetics 93, 167–172, July 11, 2ysis, genotypes (six imputed alleles at AA 13 and two SNPs)
were phased with the PHASE program17 with default pa-
rameters. Phased haplotypes were then tested for associa-
tion with FL with the use of logistic regression analysis in
PLINK. Only haplotypes with minor allele frequencies >
1% in controls were analyzed. It is interesting to note
that some rare (allele frequencies ~2%) haplotypes, such
as Phe-C-A (Table S4), are not tagged by rs10484561 and
rs2647012 but showed diverse associations across the
three study populations, and this contributed to the large
heterogeneity of the results of conditional association
analysis across the three data sets above. Further studies
withmuch larger sample sizes will be needed for evaluating
the effects of these rare haplotypes. Taken together, our
data suggest that the hexa-allelic AA 13 polymorphism
might be the primary driver of the association within the
region, whereas the diverse associations at multiple SNPs
might be due to their differential tagging effects of various
AA risk variants.
AA 13 is located in the middle of the peptide binding
groove of the HLA-DR heterodimer molecule (Figure S2)
and is thus well positioned to directly interact with bound
peptides. This position, together with positions 70, 71, and
74, has been shown to play important roles in the binding-
specificity profile of pocket 4, which is one of the most
important pockets for antigen interaction and presenta-
tion by the HLA-DR molecule.18 Chemical properties of
the side chain at this position might have a direct effect
on antigen binding and recognition within the binding
groove. The high-risk alleles at AA 13 both encode AAs
with bulky hydrophobic side chains (Phe and Tyr),
whereas the low-risk alleles encode AAs with polar or
charged side chains (Figure S2). The roles of the moder-
ate-risk alleles (encoding His and Gly) will need to be
further explored in larger samples and/or functional as-
says. Although our results seem to suggest that variation
at position 13 plays an important role in influencing FL
risk, other nearby residues within the extended HLA haplo-
type might also influence peptide binding, and detailed
functional work will be needed for proving the importance
of this single position.
Residues at AA 13 are in high LD with nearby residues at
AA 11, the second-best-associated coding variant (multial-
lelic p ¼ 3.6 3 107) in discovery GWASs (Table S5). Given
the close proximity and tight LD between the two vari-
ants, we were unable to distinguish the effects without
additional functional investigation. Variants at HLA-
DRB1 AAs 11 and 13 have previously been shown to asso-
ciate with risk of rheumatoid arthritis (RA [MIM
180300]).10 RA is an autoimmune disorder with a well-
established correlation with NHL risk (mostly with the
diffuse large B cell NHL subtype, but also with FL).19
Although the patterns of association at AAs 11 and 13
differ between RA and FL,10 the shared associations be-
tween the variants at HLA-DRB1 AAs 11–13 and FL and
RA clearly suggest the involvement of common HLA-DR
antigen-driven pathogenesis in the two different diseases.013
Further studies on large cohorts with detailed clinical in-
formation on both diseases are likely to reveal information
on the shared or distinct etiological mechanisms of RA and
lymphoma pathogenesis. In vitro biochemical studies will
be needed for testing the effects of mutants with different
combinations of AAs at these two positions on binding of
a relevant autoantigen or tumor antigen to the beta chain
of HLA-DR.
We have performed comprehensive imputation of SNPs,
classical HLA alleles, and HLA coding variants by using
a large reference panel of European subjects. Recent eval-
uation studies have demonstrated high accuracy of the
imputations of these coding variants.20 Although our
imputation confidence was high (BEAGLE r2 ¼ 0.96),
there might have been minor inaccuracies owing to the
nature of the imputation. It is possible that the GWAS
samples might have been differentiated (in terms of pop-
ulation structure) relative to the reference samples used
for the HLA imputations. We expect that this would
have led to a consistent loss of imputation accuracy and
therefore of power in both cases and controls and hence
do not expect a differential bias in terms of imputation
accuracy between cases and controls (a differential
bias could inflate type 1 error). Nonetheless, we have
confirmed the accuracy of genotypes at the most signifi-
cant imputed variants by direct Sanger resequencing and
additional HLA typing using sequence-specific primer
PCR and have demonstrated high concordance. We
have also replicated the results in two independent sam-
ple collections that were directly genotyped with ex-
perimental methods. We anticipate that there might be
haplotypes or variants, especially rare ones with allele
frequencies < 1%, that are poorly tagged and hence might
have been missed in this analysis. In particular, there
might be additional rare causal variants that could ac-
count for the residual association observed in replication
1. Our current sample size is, however, not large enough
for a conclusive assessment of these possibilities, and
the analysis of much larger reference panels and GWAS
sample sizes will be needed for accurately evaluating the
associations of these rare haplotypes.
In summary, through a comprehensive imputation and
further experimental validation analysis of the HLA region
(Figure S4), we have shown that the variants at a single
hexa-allelic AA position (13) of HLA-DRB1 influence FL
risk. This AA might account for most of the currently
observed independent SNP signals previously identified
throughGWASs in populations of European descent. There
was, however, an indication of residual associations in the
replication 1 data set, and confirming these results there-
fore warrants further study. Nevertheless, here we show
strong evidence that coding variants at a single AA position
of HLA-DRB1 contribute to multiple association signals
observed for FL. Our findings further suggest that this mul-
tiallelic AA polymorphism might explain a significant
portion of the genetic associations observed for FL within
the HLA class II region.The AmSupplemental Data
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